Cargando…
Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial
Daunorubicin pharmacokinetics (PK) are characterised by an important inter-individual variability, which raises questions about the optimal dose regimen in patients with acute myeloid leukaemia. The aim of the study is to assess the joint daunorubicin/daunorubicinol PK profile and to define an optim...
Autores principales: | Drevin, Guillaume, Briet, Marie, Bazzoli, Caroline, Gyan, Emmanuel, Schmidt, Aline, Dombret, Hervé, Orvain, Corentin, Giltat, Aurelien, Recher, Christian, Ifrah, Norbert, Guardiola, Philippe, Hunault-Berger, Mathilde, Abbara, Chadi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029035/ https://www.ncbi.nlm.nih.gov/pubmed/35456626 http://dx.doi.org/10.3390/pharmaceutics14040792 |
Ejemplares similares
-
Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia.
por: Galettis, P., et al.
Publicado: (1994) -
Progressive multifocal leukoencephalopathy after durvalumab treatment for acute myeloid leukemia: A consequence of an immune reconstitution inflammatory syndrome?
por: Vinatier, Emeline, et al.
Publicado: (2022) -
Impact of High-Dose Methotrexate on the Outcome of Patients with Diffuse Large B-Cell Lymphoma and Skeletal Involvement
por: Mercier, Mélanie, et al.
Publicado: (2021) -
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
por: Gyan, Emmanuel, et al.
Publicado: (2022) -
Acquired resistance to daunorubicin in a patient with acute myelogenous leukaemia.
por: Smith, B. J., et al.
Publicado: (1976)